Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical sirolimus for facial angiofibromas in tuberous sclerosis complex
NCT03363763Phase 2Terminated
- Sponsor
- Aucta Pharmaceuticals, Inc.
- Start
- Apr 2017
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sirolimus in facial angiofibroma, sponsored by Aucta Pharmaceuticals, Inc.. Started Apr 2017; status: terminated.
02
Drugs
sirolimus
03
Conditions
facial angiofibroma
Beyond the preview
Go deeper on NCT03363763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363763.